PRISM BioLab is a biotechnology company that specializes in drug discovery using its proprietary PepMetics® Technology to create peptides that mimic α-helix or β-turn structures.

PRISM BioLab Co., Ltd.

PRISM BioLab

PRISM BioLab is committed to maximizing the potential of its PepMetics™ Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable.

PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform. PepMetics Molecules are designed to mimic α-helix or β-turn peptides using unique, stable scaffolds.

PRISM BioLab BLOG Update! (2023/1/20)

Technology integration: From Cyclic Peptides to Small Molecules

Novel technologies and strategies bring up beautiful sprouts of innovation. In our recent paper1, a two-step strategy for designing a small molecule was demonstrated by collaboration with GeneFrontier through the integration of respective technologies. This is a fantastic example of synergy creation, leveraging each strength to develop a new and practical strategy.

More...

https://lnkd.in/dRBGHvjV

PRISM BioLab BLOG Update! (2022/12/20)

"Targeting PPI: What’s PPI inhibitor?"

PPI-targeted drug discovery strategy is intriguing field. Target identification and functional modulation are crucial for new drug discovery and development. Assay development, technological improvements of structural biology and bioinformatics allowed us to rapidly identify the target so far, even though there are still challenges. Target-based drug discovery is a current standard, and a project often starts with obvious target protein or other biomolecules. It is one of our goals to establish a clearcut strategy and methodology for PPI-targeted drug discovery.

More...
https://lnkd.in/gn78AR_J
#drugdiscovery  #ppi #prismbiolab

PRISM BioLab BLOG Update! (2022/12/16)

"What’s PPI? Introduction to Protein-Protein Interaction"

PRISM is open to all levels of scientific discussion. Our scientists would love to speak with you!

https://lnkd.in/ga7t5AYB

#drugdiscovery #ppi #prismbiolab

PRISM BioLab BLOG Update! (2022/11/16)

Cyclic peptides: Not Just A Goldmine for PPI Drug Discovery

PRISM is open to all levels of scientific discussion. Our scientists would love to speak with you! 

https://lnkd.in/g8dSzHXn

#drugdiscovery #ppi #prismbiolab

【Webinerのお知らせ】Followed by English translation

ファーマインテリジェンス・アワード・ジャパン2022受賞記念ウェビナー『低分子によるPPI阻害：新たな創薬パラダイム』のお知らせ

PRISM BioLabの独自創薬プラットフォームであるPepMetics®は、ペプチドを模倣する独自の骨格をもつ低分子によりタンパク質間相互作用の制御を可能にする技術で、新たな創薬パラダイムを創出する可能性があります。

今回のウェビナーでは、PRISM BioLabの竹原大・代表取締役が、PepMetics®技術の紹介に加え、新たな創薬パラダイムの実現に向けた多くのグローバル製薬企業との連携の状況、パートナーリング、資金調達や組織運営などバイオベンチャー経営の経験談をお話しします。

【概要】
開催日時　：2022年11月9日（水）16:00～17:00
開催形式　：オンライン（Zoom）
言　語 ：日本語
参加費 ：無料
お申し込み：https://lnkd.in/g9iSqZHn

====
Pharma Intelligence Award Japan 2022 Commemorative Webinar "PPI Inhibition by Small Molecules: A New Drug Discovery Paradigm"

PRISM BioLab's proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein interactions by small molecules with a unique peptide-mimicking backbone, potentially creating a new drug discovery paradigm.

In this webinar, Dai Takehara, President of PRISM BioLab, will introduce the PepMetics® technology and share his experiences in managing a biotech startup, including the status of collaboration with many global pharmaceutical companies, partnering, fundraising and organizational management to realize a new drug discovery paradigm. 

【Outline】
Date & Time ： November 9, 2022 (Wed.) 16:00-17:00 JST
Format ：Online (Zoom)
Language: Japanese
Participation Fee: Free of charge
Registration: https://lnkd.in/g9iSqZHn

PRISM Biolab BLOG Update!

PepMetics®: Our Engine for Paradigm Shifts on PPI Drug Discovery

PRISM is open to all levels of scientific discussion. Our scientists would love to speak with you!

https://lnkd.in/ebv7fDdt

ESMO 2022 is starting tomorrow. Come by our booth 263 to find out how we target undruggable targets with our small molecule peptide mimetics. https://prismbiolab.com
#drugdiscovery #peptides #peptidemimetics #undruggable

Visit PRISM BioLab Co., Ltd. BioLab team at booth 263 at ESMO 2022 conference to find out how we target undruggable targets with our small molecule peptide mimetics. https://prismbiolab.com
#peptides #peptidemimetics #undruggable

COM:PRISMBIOLAB

PRISM BioLab

locale

market

industry

website

crunchbase

peer of

investor of

Metrics